GlassScriptPhysician profile
Joshua C Bailey
NPI 1619292562
$1,665.16
in general payments reported to CMS, 2019-2025
23 companies · $264 in 2025
The $264 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $96.68 · 2021: $184 · 2022: $278 · 2023: $213 · 2024: $243 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $640.80 | 2019-2025 | Eterna |
| Averitas Pharma INC. | $170.64 | 2023-2025 | Qutenza |
| Spr Therapeutics, INC | $129.67 | 2024-2025 | Sprint Pns System |
| Si-Bone, INC. | $100.97 | 2023-2024 | |
| Amgen INC. | $98.07 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $89.18 | 2019 | |
| Merck Sharp & Dohme LLC | $75.44 | 2022-2023 | Keytruda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.68 | 2021 | |
| Vertos Medical, INC. | $37.09 | 2021 | |
| Janssen Biotech, INC. | $33.99 | 2022-2023 | Imbruvica, Darzalex |
| Stemline Therapeutics INC. | $26.06 | 2023 | Orserdu |
| Genmab U.S., INC. | $25.53 | 2024 | Tivdak |
| Seagen INC. | $23.42 | 2023 | Tukysa |
| Coherus Oncology, INC. | $22.50 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $20.34 | 2025 | Iovera, Zilretta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $20.29 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.33 | 2021 | |
| Boston Scientific Corporation | $17.91 | 2025 | Intracept |
| Avanos Medical | $17.88 | 2024 | Coolief* Cooled Radiofrequency |
| Pharmacyclics LLC, An Abbvie Company | $17.44 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $15.02 | 2025 | |
| Jazz Pharmaceuticals INC. | $12.64 | 2021 | |
| Astellas Pharma US INC | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.